TELA Bio, Inc. (TELA)

NASDAQ: TELA · IEX Real-Time Price · USD
8.38
-0.06 (-0.71%)
Dec 2, 2022 4:30 PM EST - Market closed
-0.71%
Market Cap 161.70M
Revenue (ttm) 38.17M
Net Income (ttm) -42.94M
Shares Out 16.76M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,567
Open 8.37
Previous Close 8.44
Day's Range 8.14 - 8.62
52-Week Range 5.15 - 13.7
Beta 1.26
Analysts Buy
Price Target 17.75 (+111.8%)
Earnings Date Nov 9, 2022

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforc... [Read more]

Industry Health Care Equipment & Supplies
IPO Date Nov 8, 2019
Employees 123
Stock Exchange NASDAQ
Ticker Symbol TELA
Full Company Profile

Financial Performance

In 2021, TELA Bio's revenue was $29.46 million, an increase of 61.77% compared to the previous year's $18.21 million. Losses were -$33.28 million, 15.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TELA stock is "Buy." The 12-month stock price forecast is 17.75, which is an increase of 111.81% from the latest price.

Price Target
$17.75
(111.81% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

1 week ago - GlobeNewsWire

TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

TELA Bio Reports Third Quarter 2022 Financial Results

MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optim...

3 weeks ago - GlobeNewsWire

TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum

MALVERN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

1 month ago - GlobeNewsWire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Oct. 28, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solut...

1 month ago - GlobeNewsWire

TELA Bio to Announce Third Quarter 2022 Financial Results

MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

1 month ago - GlobeNewsWire

TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Ma...

Study results show a low 2.6% recurrence rate and clinically meaningful improvement in patient quality of life Study results show a low 2.6% recurrence rate and clinically meaningful improvement in pati...

1 month ago - GlobeNewsWire

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

1 month ago - InvestorPlace

5 Stocks Insiders Have Built Positions in Over Past 3 Months

According to the Insider Cluster Buys screen, a Premium feature of GuruFocus, five stocks with a high number of insider buy transactions over the past three months include VOXX International Corp. ( VOX...

Other symbols: GEGRKTVOXX
3 months ago - GuruFocus

TELA Bio to Participate in Upcoming Investor Conferences

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize...

3 months ago - GlobeNewsWire

TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase

MALVERN, Pa., Aug. 23, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

3 months ago - GlobeNewsWire

TELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase A...

MALVERN, Pa., Aug. 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

3 months ago - GlobeNewsWire

TELA Bio Announces Pricing of Public Offering of Common Stock

MALVERN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

3 months ago - GlobeNewsWire

TELA Bio Announces Proposed Public Offering of Common Stock

MALVERN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

3 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -33.33% and 1.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

TELA Bio Reports Second Quarter 2022 Financial Results

MALVERN, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optim...

3 months ago - GlobeNewsWire

TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Herni...

24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios

4 months ago - GlobeNewsWire

TELA Bio to Announce Second Quarter 2022 Financial Results

MALVERN, Pa., July 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

4 months ago - GlobeNewsWire

TELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc.

MALVERN, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

4 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar?

TELA Bio, Inc. (TELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 months ago - Zacks Investment Research

TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize ...

6 months ago - GlobeNewsWire

TELA Bio Secures Up to $50 Million in Debt Financing from MidCap Financial

MALVERN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions ...

6 months ago - GlobeNewsWire

TELA Bio to Participate in Upcoming Jefferies Healthcare Conference

MALVERN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize c...

6 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

TELA Bio Reports First Quarter 2022 Financial Results

MALVERN, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize c...

6 months ago - GlobeNewsWire